BioCentury | Jan 25, 2021
Product Development

Merck shifts COVID-19 focus to therapeutics after discontinuing vaccines

With Merck’s two COVID-19 vaccines falling short of the mark, the U.S. pharma is shifting its focus to late-stage readouts this half for therapeutics to treat the coronavirus. Merck & Co. Inc. (NYSE:MRK) said Monday...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Jan 13, 2017
Financial News

OncoImmune raises $15M in series A

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital. The company's lead candidate, CD24Fc , is in a Phase II study to prevent graft versus host...
BioCentury | Jan 13, 2017
Financial News

OncoImmune completes venture financing

OncoImmune raised $15 million in a series A round led by 3E Bioventures Capital. OncoImmune Inc. , Rockville, Md. Alex Himes OncoImmune Inc....
BioCentury | Sep 19, 2016
Company News

OncoImmune, Pfizer deal

OncoImmune granted Pfizer an exclusive option to license rights to ONC-392 , a preclinical mAb against cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ), and additional anti-CTLA4 antibodies. OncoImmune is eligible to receive up to...
BioCentury | Sep 15, 2016
Company News

Pfizer, OncoImmune in deal for preclinical CTLA-4 mAb

OncoImmune Inc. (Rockville, Md.) granted Pfizer Inc. (NYSE:PFE) an exclusive option to license rights to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ) inhibitor. OncoImmune is eligible to receive $250 million in...
BioCentury | Dec 8, 2003
Company News

OncoImmune Ltd. other research news

Researchers published in the Proceedings of the National Academy of Sciences that a particular polymorphism of CD24 is associated with a >2 fold increase in the relative risk of MS in the general population (p=0.023)....
Items per page:
1 - 10 of 11
BioCentury | Jan 25, 2021
Product Development

Merck shifts COVID-19 focus to therapeutics after discontinuing vaccines

With Merck’s two COVID-19 vaccines falling short of the mark, the U.S. pharma is shifting its focus to late-stage readouts this half for therapeutics to treat the coronavirus. Merck & Co. Inc. (NYSE:MRK) said Monday...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Jan 13, 2017
Financial News

OncoImmune raises $15M in series A

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital. The company's lead candidate, CD24Fc , is in a Phase II study to prevent graft versus host...
BioCentury | Jan 13, 2017
Financial News

OncoImmune completes venture financing

OncoImmune raised $15 million in a series A round led by 3E Bioventures Capital. OncoImmune Inc. , Rockville, Md. Alex Himes OncoImmune Inc....
BioCentury | Sep 19, 2016
Company News

OncoImmune, Pfizer deal

OncoImmune granted Pfizer an exclusive option to license rights to ONC-392 , a preclinical mAb against cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ), and additional anti-CTLA4 antibodies. OncoImmune is eligible to receive up to...
BioCentury | Sep 15, 2016
Company News

Pfizer, OncoImmune in deal for preclinical CTLA-4 mAb

OncoImmune Inc. (Rockville, Md.) granted Pfizer Inc. (NYSE:PFE) an exclusive option to license rights to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ) inhibitor. OncoImmune is eligible to receive $250 million in...
BioCentury | Dec 8, 2003
Company News

OncoImmune Ltd. other research news

Researchers published in the Proceedings of the National Academy of Sciences that a particular polymorphism of CD24 is associated with a >2 fold increase in the relative risk of MS in the general population (p=0.023)....
Items per page:
1 - 10 of 11